This test is most useful if any of these apply to you.
Maybe your eyelids droop or your vision doubles by evening and then recovers after rest. These symptoms can occur when your immune system interferes with the signals that tell your muscles to move. The acetylcholine receptor blocking antibody test checks for one kind of antibody activity involved in myasthenia gravis.
Myasthenia gravis causes muscle weakness that often worsens with repeated use. Blocking antibody testing is an established laboratory test used as an adjunct in its diagnosis, usually alongside the more sensitive binding antibody test. Its proposed uses for predicting disease severity, spread beyond the eyes, or treatment response remain exploratory.
Acetylcholine is the chemical a nerve releases to make a muscle contract. It attaches to receptors on the muscle's surface where nerve meets muscle. In AChR-antibody-positive myasthenia gravis, antibodies interfere with these receptors and weaken signal transmission.
The antibodies can cause damage in several ways. Some activate complement. This group of immune proteins can damage the surface of the muscle at the nerve-muscle junction. Others cause receptors to be pulled into the muscle cell and broken down, or interfere with acetylcholine attaching to them. These activities overlap, so binding, blocking, and modulating antibodies aren't three completely separate populations.
This test uses serum separated from a blood sample. The lab mixes muscle receptors with your serum and a radioactively tagged snake toxin called alpha-bungarotoxin. A competitive radioimmunoassay measures how much the serum prevents that tracer from attaching to the receptors.
The result is reported as percent inhibition. A higher percentage means greater interference with tracer binding under the assay's conditions. It doesn't represent the percentage of receptors blocked in your body, your percentage loss of muscle strength, or your chance of having myasthenia.
The three AChR antibody tests measure different properties. In one laboratory series, 4,740 serum samples were positive on at least one of them:
| Test | What it detects | Positive among these antibody-positive samples |
|---|---|---|
| Binding | Antibodies that attach to the receptor | About 88% |
| Modulating | Antibody activity that promotes removal of receptors from the cell surface | About 70% |
| Blocking | Antibody activity that inhibits the laboratory tracer's attachment | About 65% |
Binding and blocking testing together detected about 97% of the antibody-positive samples in that series. Clinical diagnoses weren't available, so these figures describe detection among positive specimens, not how often the tests diagnose myasthenia in everyone who has it.
In an older study of 349 people with myasthenia, blocking antibodies were found in about half. Blocking was never the only positive result, partly because the modulating assay used in that study also detected blocking activity. A negative blocking result alongside a positive binding result is therefore quite possible.
A positive result can support myasthenia gravis when your symptoms and examination fit. An isolated antibody result needs more careful interpretation when the symptoms suggest another cause.
Most published diagnostic performance estimates concern AChR binding antibodies. Conventional binding testing detects antibodies in roughly 85 to 90% of people with generalized myasthenia and 50 to 70% of those with weakness limited to the eyes. Those figures don't describe the sensitivity of this blocking assay. Myasthenia can occur even when all routine AChR antibody tests are negative.
Myasthenia can also occur with a thymoma. This is a tumor of the thymus gland in the chest. A blocking result doesn't establish whether a thymoma is present.
Some people with ocular myasthenia later develop weakness in the throat, limbs, neck, or breathing muscles. Researchers have studied whether blocking antibodies help identify who will develop this more widespread form.
A Greek study followed 47 people who already had detectable AChR binding antibodies for an average of 2.8 years. Thirteen had begun with eye-only symptoms. All eight whose weakness later became generalized had blocking antibodies, while none of the five who remained ocular did.
That is a striking finding in a very small, selected group. It hasn't established a reliable way to calculate your personal risk from a blocking result. A negative result also can't guarantee that weakness will remain limited to your eyes.
Related evidence comes from a study of 223 people with ocular myasthenia. Those who later developed generalized weakness had average starting antibody levels about three times higher. That study measured serum binding antibodies, which are a different measurement from blocking activity.
A Chinese study of 148 people found blocking antibodies in about 43% of the group and 58% of those with generalized disease. Higher inhibition was associated with greater weakness and with myasthenic crisis. A crisis involves severe breathing-muscle weakness that requires ventilatory support. An association with crisis doesn't establish that a blocking result can predict when one will happen.
The findings haven't been consistent. In an Argentinian study of 75 people with AChR-antibody-positive myasthenia, higher blocking activity was associated with milder disease and findings suggesting less complement activation. This doesn't prove that blocking antibodies protect against severe disease.
Differences between the people studied and the assays used may contribute to these conflicting results, but they haven't been resolved. There is no validated blocking percentage that forecasts how weak you will become or whether you will have a crisis.
Maternal AChR antibodies can cross the placenta and cause temporary weakness in some newborns. An older study linked more severe neonatal disease to blocking activity measured using decamethonium. That research assay differed from the alpha-bungarotoxin assay used for this test.
Those findings don't establish routine blocking testing as a reliable predictor of your baby's condition. Planning observation after birth depends on your myasthenia history and the maternity and newborn teams' assessment.
Some studies of serum binding antibodies have found that falling levels accompany clinical improvement, including an observational study of 90 people. These findings concern a related antibody measurement and don't establish routine blocking measurements as a treatment-monitoring tool.
The Greek blocking study found an association between blocking activity and severity across repeated observations. Its authors explicitly cautioned that their analyses didn't establish that changes within an individual reliably followed changes in that person's symptoms.
Current guidance bases disease monitoring on weakness, examination findings, and measures of daily function. Routine antibody measurements haven't been shown to improve treatment decisions. A changing percentage can be additional information, but it shouldn't determine treatment on its own.
Evidence-backed interventions that affect your Acetylcholine Receptor Blocking Antibody level
Acetylcholine Receptor Blocking Antibody is best interpreted alongside these tests.